Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular extrasystoles02.03.04.0070.000186%Not Available
Ventricular fibrillation02.03.04.0080.000186%
Ventricular tachycardia02.03.04.0100.000140%
Vertigo17.02.12.002; 04.04.01.0030.001725%
Vision blurred17.17.01.010; 06.02.06.0070.001483%
Visual impairment06.02.10.013--Not Available
Vitamin D deficiency14.12.03.0030.000140%Not Available
Vitreous detachment12.01.04.005; 06.09.01.0020.000280%Not Available
Vomiting07.01.07.0030.003404%
Water intoxication19.07.03.004; 14.05.06.004; 05.03.03.0030.000093%Not Available
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000373%
White blood cell count decreased13.01.06.012--
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.000093%Not Available
Tubulointerstitial nephritis20.05.02.0020.000420%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.000326%Not Available
Joint range of motion decreased15.01.02.0060.000140%
Poor venous access24.03.02.017--Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000233%Not Available
Deafness unilateral04.02.01.0110.000140%Not Available
Hypoacusis04.02.01.006--
Paradoxical drug reaction08.06.01.0140.000140%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.000186%
Osteopenia15.02.03.003; 14.04.04.0040.000093%Not Available
Emotional distress19.04.02.008--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.005--Not Available
Precancerous skin lesion23.01.06.0040.000093%Not Available
General physical health deterioration08.01.03.0180.001539%Not Available
Tachyarrhythmia02.03.02.0080.000093%Not Available
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene